Departamento de Farmacologia, Universidade Federal do Paraná , Curitiba 81.530-980, PR, Brazil.
Institute of Biophysics Carlos Chagas Filho and Institute of Medical Biochemistry Leopoldo de Meis, Federal University of Rio de Janeiro , Rio de Janeiro, Brazil.
ACS Chem Neurosci. 2017 Feb 15;8(2):300-309. doi: 10.1021/acschemneuro.6b00358. Epub 2017 Jan 26.
Diazepam is a benzodiazepine receptor agonist with anxiolytic and addictive properties. Although most drugs of abuse increase the level of release of dopamine in the nucleus accumbens, here we show that diazepam not only causes the opposite effect but also prevents amphetamine from enhancing dopamine release. We used 20 min sampling in vivo microdialysis and subsecond fast-scan cyclic voltammetry recordings at carbon-fiber microelectrodes to show that diazepam caused a dose-dependent decrease in the level of tonic and electrically evoked dopamine release in the nucleus accumbens of urethane-anesthetized adult male Swiss mice. In fast-scan cyclic voltammetry assays, dopamine release was evoked by electrical stimulation of the ventral tegmental area. We observed that 2 and 3 mg of diazepam/kg reduced the level of electrically evoked dopamine release, and this effect was reversed by administration of the benzodiazepine receptor antagonist flumazenil in doses of 2.5 and 5 mg/kg, respectively. No significant effects on measures of dopamine re-uptake were observed. Cyclic voltammetry experiments further showed that amphetamine (5 mg/kg, intraperitoneally) caused a significant increase in the level of dopamine release and in the half-life for dopamine re-uptake. Diazepam (2 mg/kg) significantly weakened the effect of amphetamine on dopamine release without affecting dopamine re-uptake. These results suggest that the pharmacological effects of benzodiazepines have a dopaminergic component. In addition, our findings challenge the classic view that all drugs of abuse cause dopamine release in the nucleus accumbens and suggest that benzodiazepines could be useful in the treatment of addiction to other drugs that increase the level of dopamine release, such as cocaine, amphetamines, and nicotine.
地西泮是一种苯二氮䓬受体激动剂,具有抗焦虑和成瘾性。虽然大多数滥用药物会增加伏隔核中多巴胺的释放水平,但我们在这里表明,地西泮不仅会产生相反的效果,还会阻止安非他命增强多巴胺的释放。我们使用了 20 分钟的体内微透析采样和亚秒级快速扫描循环伏安法记录,使用碳纤维微电极在戊巴比妥钠麻醉的成年雄性瑞士小鼠的伏隔核中进行了实验,结果表明地西泮会导致伏隔核中多巴胺释放的紧张性和电诱发释放呈剂量依赖性降低。在快速扫描循环伏安法测定中,电刺激腹侧被盖区可诱发多巴胺释放。我们观察到,2 和 3mg/kg 的地西泮可降低电诱发多巴胺的释放水平,而分别用 2.5 和 5mg/kg 的苯二氮䓬受体拮抗剂氟马西尼进行给药,则可逆转这种效应。对多巴胺再摄取的测量未观察到显著影响。循环伏安法实验进一步表明,安非他命(5mg/kg,腹腔内注射)会显著增加多巴胺的释放水平和多巴胺再摄取的半衰期。地西泮(2mg/kg)可显著削弱安非他命对多巴胺释放的影响,而不影响多巴胺的再摄取。这些结果表明,苯二氮䓬类药物的药理学作用具有多巴胺能成分。此外,我们的发现挑战了所有滥用药物都会导致伏隔核中多巴胺释放的经典观点,并表明苯二氮䓬类药物可能对治疗其他增加多巴胺释放的药物(如可卡因、安非他命和尼古丁)的成瘾有用。